newsfilter
← Latest News
GlobeNewswire·

Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting

WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ:KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological